RESPONSE-ADAPTED TREATMENT WITH NIVOLUMAB AND BRENTUXIMAB VEDOTIN IN YOUNG PATIENTS WITH RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA: CHECKMATE 744 SUBGROUP ANALYSES

MLA

Maurizio Mascarin, et al. “Response-Adapted Treatment with Nivolumab and Brentuximab Vedotin in Young Patients with Relapsed/Refractory Classical Hodgkin Lymphoma: Checkmate 744 Subgroup Analyses.” Hematological Oncology, vol. 37, June 2019, pp. 56–57. EBSCOhost, https://doi.org/10.1002/hon.26_2629.

APA

Maurizio Mascarin, Laurence Brugières, Stephen Francis, Alberto Garaventa, Thomas Manley, Salvatore Buffardi, Mariana Sacchi, C Mauz-Körholz, Paul Harker-Murray, Thierry Leblanc, Auke Beishuizen, Stacy Cooper, Richard A. Drachtman, Stephen Daw, Gérard Michel, Kasey J. Leger, Kara M. Kelly, & Peter D. Cole. (2019). Response-Adapted Treatment with Nivolumab and Brentuximab Vedotin in Young Patients with Relapsed/Refractory Classical Hodgkin Lymphoma: Checkmate 744 Subgroup Analyses. Hematological Oncology, 37, 56–57. https://doi.org/10.1002/hon.26_2629

Chicago

Maurizio Mascarin, Laurence Brugières, Stephen Francis, Alberto Garaventa, Thomas Manley, Salvatore Buffardi, Mariana Sacchi, et al. 2019. “Response-Adapted Treatment with Nivolumab and Brentuximab Vedotin in Young Patients with Relapsed/Refractory Classical Hodgkin Lymphoma: Checkmate 744 Subgroup Analyses.” Hematological Oncology 37 (June): 56–57. doi:10.1002/hon.26_2629.